Table 3.
Aβ species | Aβ40 | Aβ42 | Aβ40/42 ratio |
---|---|---|---|
CP (95% CI) | 38.2 (36.7–39.6) | 36.4 (34.1–38.6) | 43.5 (36.3–50.7) |
Former/latter slope of CP (95% CI) | −0.79 (−1.02 to −0.55)/0.52 (0.46 to 0.58) | −0.10 (−0.14 to −0.06)/0.03 (0.02 to 0.03) | 0.01 (−0.07 to 0.02)/0.03 (0.02 to 0.03) |
Mixed effect models including change points and APOE | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Model includes | APOE‐ε4 | APOE‐ε2 | APOE‐ε4 | APOE‐ε2 | APOE‐ε4 | APOE‐ε2 | ||||||
Fixed effect | β (SE) | P | β (SE) | P | β (SE) | P | β (SE) | P | β (SE) | P | β (SE) | P |
Intercept | 128.93 (2.69) | <0.001 | 126.32 (2.60) | <0.001 | 15.40 (0.40) | <0.001 | 15.21 (0.38) | <0.001 | 8.41 (0.19) | <0.001 | 8.33 (0.19) | <0.001 |
Age (former CP) | −17.49 (2.10) | <0.001 | −14.26 (1.95) | <0.001 | −1.88 (0.31) | <0.001 | −1.71 (0.29) | <0.001 | −0.01 (0.14) | 0.96 | 0.12 (0.13) | 0.344 |
Age (latter CP) | 12.09 (2.10) | <0.001 | 13.42 (1.98) | <0.001 | −0.16 (0.31) | 0.614 | −0.27 (0.29) | 0.358 | 1.23 (0.14) | <0.001 | 1.44 (0.13) | <0.001 |
APOE | −9.85 (3.98) | 0.013 | 9.36 (6.18) | 0.13 | −0.54 (0.60) | 0.37 | 1.27 (0.94) | 0.177 | −0.25 (0.23) | 0.287 | −0.15 (0.35) | 0.669 |
eGFR | −0.24 (0.02) | <0.001 | −0.24 (0.02) | <0.001 | −0.03 (0.003) | <0.001 | −0.03 (0.003) | <0.001 | 0.001 (0.002) | 0.425 | 0.002 (0.002) | 0.339 |
Age × APOE (former CP) | 12.20 (4.57) | 0.008 | −11.40 (7.29) | 0.118 | 0.51 (0.68) | 0.455 | −1.30 (1.08) | 0.228 | 0.50 (0.28) | 0.08 | 0.07 (0.44) | 0.878 |
Age × APOE (latter CP) | 6.47 (4.32) | 0.134 | −1.08 (6.47) | 0.868 | −0.68 (0.63) | 0.286 | −0.23 (0.96) | 0.809 | 1.07 (0.28) | <0.001 | −0.10 (0.41) | 0.801 |
Aβ, amyloid‐beta; SE, standard error; CP, change point; eGFR, estimated glomerular filtration rate.